Fenway Health To Receive New COVID-19 Oral Antiviral Therapies

We are excited to announce that Fenway Health is one of a number of Federally Qualified Health Centers across the country selected to receive the new COVID oral antiviral therapies Paxlovid and Molnupiravir.

Both Paxlovid and Molnupiravir have received Emergency Use Authorization from the FDA for the treatment of COVID-19. Studies of Pfizer’s Paxlovid showed that it reduced the risk of COVID-19-related hospitalization or death by 88% when taken within five days of a patient’s first COVID-19 symptoms. Merck’s Molnupiravir has shown to result in a 30% reduction in hospitalizations and deaths when taken during the same time period.

Please note that we have received a limited quantity at both our 1340 Boylston St. and South End pharmacies. Providers will be following the same guidelines and recommendations around prescribing these medications as our partner hospital Beth Israel Lahey Health to ensure they are being utilized responsibly and safely.

“We are excited to have these therapies available in our arsenal to help our patients in the fight against COVID,” said Dr. Ami Multani, Medical Director of Infectious Disease.

Subscribe to our Newsletter

Want to receive email updates about what’s happening at Fenway Health? 

Share this post with your friends

Translate »